L ipoproteins play a central role in the development of atherosclerotic cardiovascular disease in humans. The plasma concentrations of lipoproteins and their metabolic fates are modulated by apolipoproteins on the surface of these lipid-rich particles. The hypothesis has been raised that genetic variation in apolipoproteins is a major determinant of the interindividual variation in susceptibility to coronary artery disease (CAD). In humans, the structural gene locus for plasma apolipoprotein E (apo E) is polymorphic: 1 " 6 three common alleles, designated e4, e3, and e2, code for three major apo E isoforms in plasma, respectively designated apo E4, apo E3, and apo E2. Apo E is a key protein in the modulation of the metabolism of the highly atherogenic apo B-containing lipoproteins. Therefore, apo E provides a good model to test the above hypothesis.
L ipoproteins play a central role in the development of atherosclerotic cardiovascular disease in humans. The plasma concentrations of lipoproteins and their metabolic fates are modulated by apolipoproteins on the surface of these lipid-rich particles. The hypothesis has been raised that genetic variation in apolipoproteins is a major determinant of the interindividual variation in susceptibility to coronary artery disease (CAD). In humans, the structural gene locus for plasma apolipoprotein E (apo E) is polymorphic: 1 " 6 three common alleles, designated e4, e3, and e2, code for three major apo E isoforms in plasma, respectively designated apo E4, apo E3, and apo E2. Apo E is a key protein in the modulation of the metabolism of the highly atherogenic apo B-containing lipoproteins. Therefore, apo E provides a good model to test the above hypothesis.
The existence of a polymorphism for such an important apolipoprotein has been a source of major interest in recent years and has raised many questions for clinicians, epidemiologists, geneticists, and biochemists. The similarities of the relative frequencies of the three common alleles among populations representing very different ethnic, cultural, and geographic settings; their different effects on •lipoprotein metabolism; and their association with certain lipid transport disorders have stimulated research aimed at a better understanding of their role in health and disease. A wealth of information 7 " 18 has accrued from studies on apolipoprotein E structure, metabolism, and function. These have considerably advanced our knowledge of the role of apo E in normal and abnormal lipoprotein metabolism, the complex interactions leading to hyperfipidemia and atherosclerosis, and the pathogenesis of type III hyperiipoproteinemia. Of major interest is the observation that the protein products of the e4 and E2 alleles have separate, and in some circumstances opposite, influences on plasma lipo-(Arteriosclerosis 8:1-21, January/February 1988) protein concentrations, a finding which leads to the hypothesis that the apo E polymorphism ranks among the major factors involved in determining interindividual differences in the initiation and progression of atherosclerosis.
The evidence associating the apo E polymorphism with altered lipid and lipoprotein levels and atherosclerosis will be reviewed here. First, the apo E gene and gene product will be considered with a brief overview of molecular biology, protein chemistry, and methods for phenotyping. Second, the impact of variation at the apo E locus on plasma lipids and lipoproteins in health and disease will be discussed. Third, the metabolic interactions accounting for the various effects of the different alleles on lipids and lipoproteins will be considered to provide a unifying interpretation as to how apo E modulates the metabolism of apo B-containing lipoproteins and their remnants. Last, direct evidence associating the apo E polymorphism and atherosclerosis will be reviewed and discussed. This review is not intended to be all-inclusive, and the reader is referred to recent reviews 7 " 18 for complementary information on some of the topics presented.
Molecular Biology, Protein Chemistry, and
Measurement of Apo E
Molecular Biology of Apo E
The gene for apo E is located on chromosome 19 where it is closely linked to the genes for apo C-l and apo C-l I and more distantly linked to the gene for the low density lipoprotein (LDL) receptor. 19 " 22 The potential for coordinate regulation of this gene complex is currently under investigation in a number of laboratories. The apo E gene organization 23 ' 24 is similar to that reported for other apolipoprotein genes, with the exception of the apo B gene. The apo E gene contains a 5' leader sequence that codes for a hydrophobic 18-amino-acid signal peptide 25 similar to other secretory proteins. It has four exons and three introns with the first intron occurring in the 5' untranslated sequence, the second near the junction of the leader sequence with the mature protein coding sequence, and the third 61 amino acids into the mature protein coding sequence. Like other apolipoprotein gene sequences, it contains multiple copies of a 66-base repeat coding for an amphipathic helix of 22 amino acids. The similar intron/ exon structure and the presence of repeating elements of similar sequence strongly support the concept of a common origin for the apolipoprotein genes. 2627 The signal peptide of the apo E protein is co-translationally cleaved and after translation, apo E is glycosylated. 17 In tissue culture, apo E is secreted primarily in a form containing multiple sialic acids. In contrast, most plasma apo E contains no sialic acid, and it is therefore likely that the sialic acids are removed by a sialidase activity in a post-secretory process. Apo E has also been reported to be aerated 2 * but the physiological significance of both glycosylation and acylation are unknown. In contrast to apo A-l, apo A-ll, and apo C-ll, apo E is secreted as a mature protein without a pro-peptide at its amino terminus. 25 Apo E is synthesized primarily in the liver, but it is also synthesized by a number of different tissues in the body including the spleen, kidney, adrenals, gonads, brain, macrophages, and astrocytic glia. 29 " 33 However, the roles of the nonhepatic, de novo synthesized apo E in lipid and lipoprotein metabolism in these tissues, in the immune system, and in the nervous system are not well understood. Of particular interest is the fact that in four members of a family who synthesize no apo E, the only apparent abnormality is in the plasma lipoprotein transport system; the neurologic, endocrine, and immune functions are normal. 34 
Protein Chemistry of Apo E
The sequences of the three common isoforms were initially determined by direct protein sequencing by Rail et al. 35 The three isoforms differ by amino acid substitutions at one or both of two sites (residues 112 and 158) on the 299-amino-acid chain of the mature apo E molecule. E4 has arginine and E2 has cysteine at both sites, while E3 has cysteine at site 112 and arginine at site 158. Therefore, apo E4 has one more positive charge compared to apo E3, while apo E2 has one less. In addition to the charge alterations, apo E2 and apo E3 have reactive free sulfhydryl groups which can form disulfide bonds with other free sulfhydryl-containing proteins; 36 ' 37 ' M this may have important effects on the function of apo E. From the protein sequence of apo E, it has been estimated that its secondary protein structure consists of 62% alpha helix, 9% beta sheet, 11% beta turns, and 18% random coil. 35 The amphipathic a-helices are probably responsible for binding of lipids to apo E. There is a clustering of positive charges from amino acids 134 to 158. This portion of the molecule binds to the LDL receptor and to heparin; 3940 it also contains an epitope for an apo E monoclonal antibody that blocks binding of apo E to its receptors. 41 In addition, there is evidence for a second region in the carboxy end of the molecule that may be a receptor/heparin binding site. 42
Methodology for Apo E Phenotyplng
The three common isoforms are determined by three alleles of the gene for apo E. These three apo E alleles determine six genotypes; three homozygous, designated E4/E4, e3/e3, e2/e2, and three heterozygous, designated e4/e3, e3/e2, and e4/e2. The corresponding plasma phenotypes are inherited in a codominant fashion and, in accordance with common usage, they will be designated in this text E4/4, E3/3, E2/2, E4/3, E3/2, and E4/2. 6 It would be more correct, however, to express the phenotypes resulting from the homozygous genotypes simply as E4, E3 and E2 since only one isoform is present in plasma. Other rare variants have been described, including a null allele. Some have been identified by current methods for apo E phenotyping, but in a few cases the mutant protein is indistinguishable from the common isoform by gel electrophoresis. For the purpose of this review it will be assumed that for the common isoforms, the phenotype reflects the genotype.
The charge differences in the common allelic forms of apo E allow one to determine the apo E phenotype of an individual by isoelectric focusing (IEF). A number of methods for apo E phenotyping have been published (see reference 17 for a review). In most methods, isolated and delipidated very low density lipoprotein (VLDL) from plasma is subjected to IEF using a pH gradient between pH 4 and pH 7. Figure 1 illustrates the six common apo E phenotypes using the method of Bouthillier et al. 43 In cases where the phenotype is uncertain because of charge alterations secondary to the presence of varying amounts of sialic acid in addition to the genetically determined charge differences, three methods are commonly used to resolve the uncertainty.
First, the VLDL can be treated with neuraminidase to remove the interfering sialic acids before focusing. 5 Second, the VLDL sample can be treated with cysteamine which adds a positive charge to the sulfhydryl group of the cysteine residues. 44 After treatment with cysteamine, apo E2, which has two cysteines, is expected to move two charge units toward the cathode; apo E3, with one cysteine, to move by only one unit; and apo E4, without cysteine residues, not to change position. Thus, both E2 and E3 are found at the position of E4 after cysteamine treatment. In a subject with a homozygous genotype, the relative intensities of the apo E IEF bands (free and sialylated isoforms) will be unchanged because the apo E in each band has the same number of sulfhydryl groups. Each band will be equally altered in terms of charge and displacement on the gel after cysteamine treatment. In a subject with a heterozygous genotype, however, the bands differ both in apo E content and in number of free sulfhydryls. Therefore, after cysteamine treatment not only will the apo E IEF bands change in position, but the relative intensities of the two major bands will also change. This procedure can help to confirm the nature of the isoforms in both the homozygous and the heterozygous states and can also provide a means to disclose rare mutants, when isoforms do not move as expected after cysteamine treatment.
A third method is to perform two-dimensional gel electrophoresis on the delipidated VLDL. 5 The sialylated forms of apo E have a slightly higher molecular weight on the twodimensional gel. Therefore, the higher molecular weight sialo forms of apo E can be differentiated from the lower molecular weight asialo forms. Recently, an interesting new method for determining apo E phenotype was developed. This involves IEF of delipidated plasma and detection of apo E by immunoblotting with an anti-apo E antibody. 45 ' 48 The advantages of this method are that ultracentrifugation is not necessary and only very small amounts of plasma ( 
Effect of the Apo E Gene on Plasma Llplds, Lipoprotelns, and Apolipoproteins In the Population at Large and In Normolipldemlc Subpopulatlons
The gene coding for apo E is one of many genes that have been suggested as candidates for establishing predisposition to the development of CAD. 48 ' 49 For the population at large, the consequences of allelic variation at this gene locus may be measured in terms of: 1) the relative frequencies of the alleles, 2) the impact of allelic differences on interindividual variation in traits that are predictors of health and disease, and 3) the contribution of allelic differences to the prediction of disease, independent of their effect on the lipid and lipoprotein traits that link the genotype to the endpoint (i.e., the effect on thrombosis, arterial wall response, or unmeasured phenotypes). The greater the frequency of an allele, the higher the proportion of individuals in the population who have the predisposition to express its effects. The impact of an allele on variability in a population is measured by the product of the relative frequency of the allele and the size of the phenotypic deviation associated with the allele. A rare allele that predicts a very large deviation from the mean of the population and a common allele that predicts a relatively small deviation may each have a similar impact on the total amount of phenotypic variability.
The relative frequencies of the apo E alleles for populations that represent a broad range of ethnic, cultural, and geographical differences will first be summarized. The impact of this allelic variation on the normal variation of lipid and lipoprotein levels in the population at large will then be reviewed. Finally, those investigations that compare healthy with diseased groups to obtain an estimate of the contribution of allelic variants at the locus coding for apo E to a prediction of CAD that is independent of information about lipid, lipoprotein, and apolipoprotein phenotypes will be considered.
Relative Allele Frequencies
Allelic variations at the genetic locus responsible for the common apo E phenotypes have been studied by many laboratories. A review of relative allele frequencies estimated for South American Indian, 50 Chinese 51 (Chen BS et al., unpublished observations), Japanese, 52 ' M and Caucasian 3 ' 54 " 61 populations is presented in Table 1 . The studies are ordered within groups according to the relative frequency of the e3 allele. Sampling designs vary from study to study. They have included blood donors, normolipidemic volunteers, outpatients, participants in a preventative medicine program, and random samples from a well-defined geographic region. Despite the obvious heterogeneity among studies in the population represented by the sampling design, a number of generalizations can be made. With only one exception (South American Indians studied by Asakawa et al. 50 ), each of the three common alleles is present in all of the population groups studied thus far. The e3 allele is the most common form of the gene in every population. Except for the sample of Chinese people living in Montreal, the e4 allele is the next most common allele. These data suggest a number of population-specific inferences. The relative frequency of the e3 allele is less than 0.79 in every Caucasian sample, whereas in all other samples it is greater than 0.82. The average relative frequency of e3 for the two samples of Chinese, 0.852, is not significantly different from the average for the three Japanese samples, 0.851, but both averages are significantly greater (p < 0.001) than the Caucasian average, 0.769. All pairwise comparisons between ethnic groups of the relative allele frequencies estimated for each of the groups are significantly different at the 0.001 level of probability. The relative frequency of e2 is lowest in Japanese populations, while that of e4 is lowest in the Chinese samples. Chinese and Caucasian samples are similar for the frequency of e2 but significantly different (p < 0.001) for the relative frequencies of the e3 and e4|alleles. The Japanese samples are significantly different (p < 0.001) from the Caucasian samples for all three allele frequencies. Compared to the Caucasian populations, a higher relative frequency of e3 is associated with a substantially lower relative frequency of the e4 allele in the Chinese and moderately lower relative frequencies of both the e2 and the e4 allele in the Japanese.
There is also statistically significant variation in the allele frequencies among the studies of Caucasian populations.
The frequencies in the sample from Helsinki, Finland 59 are significantly different (p < 0.001) from all others in the group. The relative frequency of e2 in Finns is half the overall Caucasian average and one-third as large as the estimates presented for the Christchurch 58 and Nancy 55 populations. On the other hand, the estimate of the relative frequency of e4 for the Finnish population is 50% higher than the estimates for the other Caucasian populations and significantly different (p < 0.01) from all other samples in the group. There is no statistically significant evidence for heterogeneity of the relative allele frequencies among the Framingham, 80 Munster, 6162 Marburg, 3 Grampian, 57 Ottawa, 54 and Nijmegen 56 populations. The Nancy and Christchurch estimates are not significantly different from each other at the 0.10 level of probability. Of the first group of populations, all except Ottawa and Nijmegen are signifi-cantly different from Nancy and Christchurch. In the Nancy and Christchurch samples, a lower frequency of the e3 allele is associated with higher frequencies of both the E2 and E4 alleles, a difference similar to that observed for the comparison of Caucasians in general with the Japanese. These data suggest that although the Caucasian populations are characterized by a lower relative frequency of the e3 allele than the Japanese and Chinese populations, there is no consistent difference with respect to the other two common alleles. It is concluded that the contribution of the apo E gene locus to the genetic distance between the Caucasian and the Chinese and Japanese populations is primarily attributable to the relative frequency of the e3 allele. The observed heterogeneity among the Caucasian populations studied thus far is associated with differences in the relative frequencies of the E2 and E4 alleles.
Sing and Davignon 54 have pointed out that the similarity of these allele frequencies among the Caucasian populations is far greater than one would expect from the distribution of other polymorphic blood and serum markers among the same populations. The available studies (Table 1) suggest that there may be a pattern of heterogeneity of allele frequencies among more distantly related populations. Further studies of non-Caucasian populations are necessary to establish whether there is greater heterogeneity of the relative allele frequencies between than within population groups. Higher e3 frequencies in Chinese and Japanese populations may indicate a role for the e3 allele in determining the lower susceptibility to CAD observed in these populations. A much higher frequency of the e4 allele, but not the e2 allele, in the Finnish population, where risk of CAD is quite high compared to Japan, would further suggest that this allele may contribute to the observed differences in the prevalence of CAD among populations.
No comparative studies to test this hypothesis have been completed. However, it seems likely that the modest differences in allele frequencies that have been observed will explain no more than a small fraction of the difference in prevalence of CAD between high-and low-risk populations.
Few studies have considered the distribution of the common apo E alleles among sex and age groups within populations. Table 2 summarizes statistics derived from three studies of the population at large: Framingham, 60 Munster, 61 and Nancy. 63 Data presented by Ordovas et al. 60 for the Framingham community show no evidence for a statistically significant difference of allele frequencies: 1) between those below 45 years of age and those 45 to 71 years of age ignoring sex, 2) between sexes ignoring the age cohort, or 3) between sexes within either age cohort. These findings are consistent with the comparisons of parent and offspring subsamples of Nancy and between sexes in the Nancy and Munster studies. Cumming and Robertson 57 presented pooled relative allele frequencies in their report because they did not find evidence for differences between the sexes.
Impact of Allellc Variation
Utermann and coworkers 64 ' ^ were the first to observe that in the normal population, individuals carrying the e2 allele had lower levels of plasma cholesterol and LDL cho- lesterol concentrations than individuals with the e3/e3 genotype. Conversely, Bouthillier et al. 43 and Davignon et al., 66 studying lipoprotein profiles in normolipidemic offspring of informative matings among people with different apo E phenotypes, were the first to show that the subjects carrying the e4 allele had higher levels of cholesterol and LDL cholesterol than did subjects homozygous for the e3 allele. These studies have since been confirmed and extended. Furthermore, it has become possible to measure the relative impact of each separate allele on lipids, lipoproteins, and apolipoprotein parameters. The impact of allelic variation for apo E on the interindividual differences in serum cholesterol, triglycerides, and high density lipoprotein (HDL) cholesterol has been considered in seven of the populations listed in Table 1 . Fewer studies have estimated the association between the apo E alleles and the levels of one or more of the apolipoproteins. We will consider the impact of allelic variation first on apolipoprotein concentrations and then on cholesterol, triglycerides, and HDL cholesterol.
Utermann 12 ' M studied the association between the level of serum apo E and the genotypes determined by the three common alleles. He found that those genotypes with the e2 allele had the highest average level and those with the e4 allele had the lowest average. Sing and Davignon 54 and Utermann 64 reported that the lowest apo B levels were associated with the e2/e2 genotype, while the highest average levels were associated with the E4/E4 and E4/E3 genotypes. In view of the apparent role of apo E in the regulation of lipid metabolism (discussed below), future studies of the effects of structural variability in the apo E molecule on the levels of the apolipoproteins will help in developing an understanding of the links between genetic variation and the regulation of lipid and lipoprotein levels.
In addition to the studies of the apolipoprotein effects mentioned above, the roles of the E2, e3, and E4 alleles in determining serum cholesterol, triglyceride, and HDL cholesterol levels were considered in seven studies of the population at large. 3 ' 54>55 ' 5960 ' 61 ' 87 There was no evidence for a consistent relationship between the apo E genotype and the triglyceride and HDL cholesterol levels. However, the association between an individual's apo E genotype and the average cholesterol level was remarkably consistent among the studies. The average serum cholesterol for each of the six common apo E genotypes is given in Table 3 . The estimates of the population average range from 174 mg/dl (Ottawa, Canada) to 230 mg/dl (Nancy, France). The sample from Ottawa did not include hyperiipidemic individuals, whereas the Nancy sample was unselected for hyperlipidemia. Regardless of the sample mean, individuals with the e2/e2 genotype have the lowest, while individuals carrying the e4 allele have the highest, average level. The genotype means rank: e2/e2 < E3/E2 < E3/E3 < e4/e -in every study. These findings imply that the quantitative impact of an individual's apo E genotype on the level of cholesterol is independent of the average cholesterol level for the population. These studies also suggest that any differences in ecological factors and genetic background among these populations have little influence on the role of apo E polymorphism in determining individual differences in plasma cholesterol. Therefore, any difference in risk between, for example, Ottawa and Helsinki that may be associated with the apo E gene is attributable to differences in relative frequency and not to a change in the phenotypic expression of any particular apo E genotype. Further studies of Japanese and Chinese populations, in whom risk for CAD is less than in Caucasian populations, are necessary to confirm the independence of the genotypic effects and population-specific ecological and genetic factors. Figure 2 shows the average cholesterol effect of each of the common alleles, e2, e3, and e4, estimated for the seven populations presented in Table 3 . The average effect of an allele is defined as the expected deviation of the mean of the subgroup of individuals carrying that allele from the population mean. Sing and Davignon 54 give the formula for the computation of the average effect of an allele, which is a measure of the impact of an allele on the level of the trait. In every population studied thus far, the total serum cholesterol level is decreased in carriers of an e2 allele and elevated in carriers of an E4 allele. The estimate for the average effect of the e3 allele is nil in every case. The difference between the average effects of e2 and e4 ranges from 13 mg/dl in Asahikawa 67 and Marburg 3 to 30 mg/dl in Nancy. 54 The "cholesterol-lowering" effect of the e2 allele is two to three times the "cholesterol-raising" effect of the E4 allele, depending on the population studied. No other gene product has been identified as having as large a contribution to the determination of individual differences in the level of serum cholesterol in the normal range of variability.
The impact of an apolipoprotein polymorphism on the interindividual variance of serum cholesterol in the population at large is estimated by the ratio of the variance among genotypic means to the total phenotypic variance. Sing and Davignon 54 estimate that for apo E this ratio is 0.07 for a sample of unrelated individuals from Ottawa, Canada. Using analytical strategies developed by Boerwinkle et al. 68 for samples of related individuals, Boerwinkle and Sing 63 estimate that this ratio for the Nancy population ranges from 0.065 to 0.088 depending on the method of estimation used. In Figure 3 , this information from the Nancy Study 63 is combined with that from studies of other populations to obtain an approximation of the causes of age-, height-, and weight-adjusted plasma cholesterol variability in a Caucasian population. Although the locus for familial hypercholesterolemia has a large effect on an individual's cholesterol level, it does not make a large contribution to the cholesterol variability in the general population because the mutant alleles are rare. Sing and Orr 69 found that four polymorphic blood and serum markers account for less than 1% of the variability because the allelic effects of each are small. The gene coding for apo E makes a large contribution to total phenotypic variability because the average effects of the three polymorphic alleles are moderate. 63 Recently, Humphries et al. 49 reported that an Xba I polymorphism of the gene coding for apolipoprotein B predicts as much as 14% of the interindividual variability observed in a sample from London, England. The combined estimates from these studies suggest that as much as 24% of the interindividual phenotypic variance of serum cholesterol may be associated with only three of the many loci that are candidates for involvement in the regulation of lipid metabolism.
It should be emphasized that no one study has simultaneously estimated the contribution of all of the loci presented in Figure 3 . Because allele frequencies vary among populations and because the effects associated with these loci may not be independent, it is likely that 24% is an overestimate of the genetic variance attributable to these three genes for any specific population. Nonetheless, it is apparent that the loci coding for apo B, apo A-IV, and apo E may explain a large fraction of the genetic variance of total serum cholesterol. It is reasonable to conclude, from these first studies to characterize the genes responsible for the genetic variance of cholesterol, that the number of loci involved may not be as great as implied by the polygene hypothesis. 69 The apo E polymorphism plays an important role in determining interindividual differences in cholesterol levels in every population studied thus far. Consistent effects among populations of this polymorphism on the levels of serum triglycerides and HDL cholesterol are not apparent. Such effects may be small and population-specific. The effect of this structural polymorphism on the quantitative levels of the B and E apolipoproteins suggests a relationship between these gene products and levels of the lipids and lipoproteins. Variations in the magnitude of the respective effect of the e2 and the e4 alleles on plasma cholesterol in certain populations or ethnic groups have been tentatively attributed to an eco-genetJc interaction. 70 Predisposition to a complex disease like CAD is determined by multiple genetic and environmental factors, so it is unlikely that any one genetic locus will predict the entire subgroup of individuals who will be affected. 71 The central question then becomes what fraction of the CAD is predicted by allelic variation at the gene locus? Further, is the contribution of such a locus to the prediction of risk increased by, decreased by, or independent of other genetic and environmental risk factors for the disease? Efforts to determine the ability of apo E to predict CAD have focused on case-control studies, many of which may not be representative of the population at large. The ultimate impact of apo E variability on CAD will be discussed in the last section of this review.
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Effect of the Apo E Gene on Plasma Liplds, Llpoprotelns, and Apollpoproteins in Hyperlipldemlc and Dyslipidemlc Individuals
Dysbetallpoprotelnemla and Type III Hyperiipoproteinemia
The apo E phenotype has been determined in individuals with various types of hyperiipoproteinemia, and the relationship between the apo E phenotype and the lipid and lipoprotein concentrations has been quantified. The most striking association is the well-described higher prevalence of the E2/2 phenotype in subjects with type III hyperiipoproteinemia. 2 ' 4 This hyperiipoproteinemia is characterized by an accumulation of remnants of triglyceride-rich lipoprotein particles in plasma. It has been associated with several genetic abnormalities affecting lipoprotein metabolism. These include a number of different mutants of apo E, 35 -72~7e some of which seem to lead to dominantly inherited type III hyperiipoproteinemia, 7475 apo E deficiency, 34 hepatic lipase deficiency 77 (although the B-migrating VLDL remnant particles are not as cholesterol-enriched as in most type III subjects), and possible defects in the lipoprotein remnant receptor. Most commonly, type III hyperiipoproteinemia occurs in association with the E2/2 phenotype. 1 " 5 ' 7 " 187879 Although most people with type III hyperiipoproteinemia have this phenotype, the converse is not true; fewer than 5% of individuals with the E2/2 phenotype have type III hyperiipoproteinemia. In studies of large families in which the proband has type III hyperiipoproteinemia, hyperiipidemia in other family members is distributed independently of the e2 allele. 78 ' ™ In addition it has been shown that apo E from hyper-, normoor hypocholesterolemic subjects with an E2/2 phenotype has equally defective binding to the LDL receptor in vitro. 80 The data are most consistent with the notion that the E2/2 phenotype is a necessary, but not sufficient, requirement for the expression of type III hyperiipoproteinemia in humans.
In individuals with an E2/2 phenotype who are otherwise normolipidemic, the presence of apo E2 results in an accumulation of remnants of triglyceride-rich lipoprotein particles and a decrease in plasma LDL concentration. In subjects with the E2/2 phenotype who have an added metabolic abnormality that leads to hyperiipoproteinemia, the hyperiipoproteinemia is phenotypically expressed as type III 78 ' re ( Figure 4 ). Several secondary factors may thus promote type III hyperiipoproteinemia in a subject with the E2/2 phenotype: 1) a genetic hyperiipoproteinemia such as familial combined hyperiipoproteinemia and perhaps familial hypertriglyceridemia; 2) a hormonal disturbance such as hypothyroidism, estrogen withdrawal, pregnancy, or diabetes mellitus; 3) an environmental factor such as a dietary imbalance leading to obesity; 4) an adverse response to drugs leading to hyperiipoproteinemia; or 5) changes associated with increasing age. If the above factors are corrected, the hyperiipidemia may resolve but the raised plasma concentration of remnant particles will persist. Therefore, in most individuals the type III hyperiipoproteinemia results from a complex interaction between an E2/2 phenotype and an additional metabolic abnormality associated with hyperiipidemia.
Association of Apo E Phenotypes with Other Forms of Hyperiipidemia
Population studies have demonstrated an increased prevalence of the e2 allele in individuals with hyperiipidem j a 65,66,81,82 except in one study from New Zealand. 83 This enrichment in the frequency of the e2 allele was associated with hypertriglyceridemia 65 ' 66 ' 81 ' 82 ' 84 ' 85 and attributed to an increased prevalence not only of the E2/2 phenotype 82 but also of the E3/2 and E4/2 phenotypes.88.81.84,85 j^j g w a s observed in groups of patients with hypertriglyceridemia alone as well as in those with mixed hyperiipidemia (elevations of both cholesterol and triglycerides) and the secondary hyperiipidemia associated with diabetes mellitus. 84 A higher prevalence of the e4 allele 81 ' M or of the E4/4 phenotype w was associated with hypercholesterolemia in some studies. When subjects with hypertriglyceridemia and a type IV hyperiipoproteinemia phenotype were evaluated in more detail, a higher prevalence of the e2 allele was found only in the group of subjects with normal apo B levels, and subjects with combined hypertriglyceridemia and hyperapobetalipoproteinemia had a normal apo E isoform distribution. 85 A higher prevalence of the apo E4 isoform has been shown in subjects with type V hyperlipoproteinemia, 87 although this has not been a uniform finding. 88 In one small study, there was no significant association found between the apo E phenotype and type I hyperlipoproteinemia. 89 A number of rare mutants of apo E have been described, some of which have been associated with hyperiipoproteinem j g g 25, 34, 60, 72-76, 90, 91, 92 In summary, despite differences in the ways the studies were performed and the results obtained, there were consistent tendencies for individuals with hypertriglyceridemia and mixed hyperlipidemia to have a higher prevalence of the e2 allele while subjects with hypercholesterolemia had a higher prevalence of the e4 allele. In addition, there may be a higher frequency of the e4 allele in subjects with type V hyperlipoproteinemia.
Pathophysiologlcal Interpretation
Metabolism
In Vitro Investigations
The modulation of lipoprotein metabolism by apo E has been extensively investigated both in vitro and in vivo. The in vitro studies have primarily involved the use of recombined particles containing apo E and phospholipid, apo Econtaining lipoprotein particles, and cholesterol-enriched lipoprotein particles containing only apo E (termed HDLc). 9 ' *°- 93 -102 The results of these in vitro studies have demonstrated that apo E can bind to two distinct receptors, the LDL receptor and a lipoprotein remnant receptor. The LDL receptor is present on most mammalian cell types studied. It binds both apo E and apo B-100-containing lipoproteins. The remnant receptor is present primarily on hepatocytes and binds only apo E-containing lipoproteins. Apo E2 has an extremely low affinity for binding to both the LDL and apo E receptors, while the binding of apo E4 is indistinguishable from that of apo E3. 9 ' x Other rare mutant forms of apo E associated with type III hyperlipoproteinemia have a variable degree of decreased binding affinity to these receptors. 721 ^7 5 ' 7e In addition, studies using chylomicrons and chylomicron remnant particles have indicated that nascent chylomicrons bind poorly to lipoprotein receptors, that chylomicron remnants will bind to the remnant receptor and to the LDL receptor, and that binding of remnant particles to the lipoprotein remnant receptor is apo E-mediated and does not involve the binding of apo B-48 to a cell surface receptor. 93 ' 97 The role of apo E in modulating the catabolism of apo B-100-containing VLDL has also been investigated. 4094 These studies have demonstrated that remnants of large VLDL, as well as VLDL from hypertrigtyceridemic individuals, utilize apo E, and not apo B-100, as the ligand for binding to cell surface receptors. On the other hand, smaller VLDL and IDL particles use both apo E and apo B-100 as binding ligands, and LDL uses only apo B-1 00 for binding to the LDL receptor. The C apolipoproteins can also modulate the apo E-mediated catabolism of VLDL by the liver by inhibiting apo E-dependent binding and degradation of these lipoprotein particles. 98 ' 10° Therefore, these in vitro studies indicate that apo E modulates the binding and catabolism of chylomicron remnants, large VLDL and VLDL remnants, and that apo E2, but not apo E4, has lower receptor binding affinity than apo E3, while apo E4 has the same binding affinity as apo E3. In addition to the receptor binding function of apo E it has been demonstrated in vitro that apo E is necessary for the efficient conversion of VLDL remnants to LDL. 101 ' 102 
In Vivo Investigations
The in vivo metabolism of apo E has been investigated with results indicating that both apo E2 and apo E4 are metabolically different from apo E3. 18 ' 103 - 108 The different apo E forms had different affinities for lipoprotein particles. Radioiodinated apo E2 and apo E3 were injected intravenously into normolipidemic E3/3 subjects; apo E2 was associated less with VLDL, intermediate density lipoprotein (IDL), and LDL and more with HDL and the lipoprotein-free fraction when compared to apo E3. 18 In addition, apo E2 was catabolized more slowly than apo E3 in normal subjects and in normolipidemic and hyperfipidemic subjects with an E2/2 phenotype. 104 -106 Apo E4 also showed differences from apo E3, but these were opposite to those of apo E2. 10S Apo E4 was associated more with VLDL, IDL, and LDL and less with HDL and the lipoprotein-free fraction. Apo E4 was also catabolized more rapidly than apo E3 in subjects with E3/3 and E4/4 phenotypes. The catabolic rates for the different forms of apo E correlate well with the plasma concentrations of apo E: individuals with an E2/2 phenotype have the highest, E3/3 subjects have an intermediate, and those with an E4/4 phenotype have the lowest plasma concentrations.
Interestingly, this inverse relationship between the apo E isoform associations with VLDL and their plasma concentration is what has allowed apo E to be phenotyped on VLDL; apo E2 has a lower affinity for VLDL but a higher plasma concentration, while the inverse is true for apo E4. Therefore, even in the face of up to three-to five-fold differences in the plasma concentration between apo E2 and apo E4, they are both represented in approximately equal amounts on VLDL in a heterozygous subject.
The in vivo metabolism of apo E2 reflects the apo E2 binding studies showing defective metabolism of apo E2, but the apo E4 results are at variance with the in vitro data. In the in vitro experiments apo E3 and apo E4 metabolism were indistinguishable, while the in vivo experiments demonstrated that apo E4 distributed differently on lipoprotein particles and was catabolized more rapidly than apo E3. The etiology of these differences is currently under investigation.
Apo E has also been shown to be important in modulating the catabolism of apo B-containing lipoproteins in vivo. Utilizing oral vitamin A as a marker for intestinally derived lipoprotein particles, it was demonstrated over 10 years ago that patients with type III hyperlipoproteinemia have slower clearance of chylomicron remnants than normal subjects. 107 At approximately the same time, type III patients were also shown to have delayed clearance of VLDL remnants. 108 Both of these findings have been confirmed and extended recently. The catabolism of apo B-48-containing lipoprotein particles was markedly delayed in subjects with the E2/2 phenotype 109 or with apo E deficiency. 34 These alterations in lipoprotein metabolism have also been observed in normolipidemic e2 homozygotes. Nor-molipidemic subjects with an E2/2 phenotype had an elevated and prolonged post-prandial hypertriglyceridemic response after a high-fat meal 106 and delayed clearance of chylomicron remnants. 110 The catabolism of apo B-100-containing VLDL particles is also abnormal in type III hyperlipidemia. The initial lipolytic phase of VLDL catabolism was normal in type III subjects (the conversion of large VLDL particles to small VLDL particles), but the further catabolism and removal of remnant particles was delayed. 34 ' 108 ' 109 ' 111 The in vivo and in vitro results are consistent with apo E2 being metabolically "abnormal", leading to delayed catabolism of apo B-containing remnants of triglyceride-rich lipoproteins. The in vivo data demonstrate that in individuals who have the E2/2 phenotype or an apo E deficiency, there is delayed catabolism of lipoprotein remnant particles of both intestinal and hepatic origin.
The metabolism of apo B-100-containing LDL is also modulated by apo E. As described above, subjects with apo E deficiency or an E2/2 phenotype who are either normolipidemic or hyperlipidemic have decreased plasma LDL cholesterol and apo B concentrations. The metabolism of LDL in these subjects has been studied with the following results. 112113 First, these persons catabolize LDL more rapidly than subjects with an E3/3 phenotype. Second, there is a decreased production of LDL in these subjects. Third, when injected into normal subjects, LDL from apo E2/2 subjects are metabolically different, being catabolized more slowly than LDL from E3/3 subjects. Individuals with an E4/4 phenotype have elevated concentrations of LDL cholesterol and apo B, but little is known of the kinetics of LDL metabolism in these subjects.
It has recently been proposed that the apo E phenotype modulates the intestinal absorption of cholesterol in humans. When the response of an E3/3 phenotype was used for comparison, individuals with an E3/2 phenotype had a lower rate of intestinal absorption of cholesterol, while those with an E4/3 phenotype had a higher rate. 114 The mechanism of this modulation is unclear, but if these observations are confirmed, another important role of apo E in lipid and lipoprotein metabolism may be revealed.
Mechanisms Whereby Apo E Modulates the Metabolism of Apo B-Contalnlng Lipoproteins
A unifying hypothesis is presented in Figure 5 to explain the lipid and lipoprotein dysfunctions associated with the apo E2 and apo E4 phenotypes. 15 ' M ' 105 The catabolism of apo B-100-and apo B-48-containing lipoprotein particles is a complex process that involves at least two different cell surface receptors and two apolipoprotein ligands for these receptors, in addition to the exchange of components with other lipoproteins and enzymes which modify the lipoprotein particles. Triglyceride-rich lipoprotein particles are secreted by the intestine, and after secretion the triglycerides are hydrolyzed by lipoprotein lipase. The apo B-48-containing intestinal remnant particles are then catabolized by an apo E-mediated remnant receptor endocytotic pathway in the liver. Similarly, hepatic triglyceride-rich lipoprotein particles are secreted by the liver, and after secretion the triglycerides are also hydrolyzed by lipoprotein lipase. The resulting apo B-100-containing remnant particles can then be further metabolized by three different pathways. The remnants can be catabolized directly by hepatocytes through an apo E-mediated remnant receptor pathway, they can be directly catabolized by an apo B-or apo Emediated LDL receptor pathway, or they can be further metabolized to LDL by a poorly understood mechanism that involves hepatic lipase but is also modulated by apo E. The resulting LDL particles are catabolized by the LDL receptor pathway utilizing apo B as the receptor ligand.
Apo E2 is metabolically impaired compared to apo E3 in the sense that processes dependent on apo E (such as interaction with receptors and/or enzymes and the clearance of apo E2 from plasma) occur at a lower rate. This results in delayed catabolism of both chylomicron and VLDL remnants and an accumulation of these particles in plasma. There is a lower rate of apo E-mediated conversion of VLDL remnants to LDL, also resulting in an accumulation of VLDL remnants in plasma and a lower production rate of LDL. The lower rate of transport of cholesterol-rich remnant particles into the liver and the decreased rate of LDL formation leads to an up-regulation of LDL receptors. These apo E2-mediated alterations in lipoprotein metabolism result in higher plasma concentrations of triglyceride-and cholesterol-containing remnant particles and in a lower level of cholesterol-rich LDL particles. The net alteration in plasma lipid levels is an increase in plasma triglyceride concentration and a decrease in cholesterol concentration. When this inefficient catabolic mechanism is further stressed by environmental, hormonal, or genetic factors that result in an increased production rate for VLDL, marked elevation in plasma lipids and type III hyperlipoproteinemia develops.
There are fewer experimental data pertaining to the modulation of lipoprotein metabolism by apo E4, but most of the results are consistent with apo E4 having an effect opposite to that of apo E2, with the following consequences. Chylomicron and VLDL remnants will be catabolized at a higher rate, with delivery of cholesterol and triglyceride to the liver. Also, VLDL remnants will be converted to LDL at a higher rate, resulting in a higher LDL production rate. The higher rate of transport of remnant cholesterol into the liver and the higher rate of conversion of VLDL remnants to LDL will lead to a down-regulation of LDL receptors. This will result in a higher plasma LDL concentration and a lower concentration of remnant particles. Since remnant particles are present in normal subjects in very small quantities, the postulated lower level of remnants would be difficult to detect. The net apo E4-mediated alteration in plasma lipid levels would, therefore, be a higher cholesterol concentration with little alteration in the triglyceride concentration.
An important and poorly understood aspect of apo Emediated alterations in lipoprotein metabolism is how apo E-mediated catabolism of VLDL and remnant particles modulates the intracellular synthesis and assembly of lipids and apolipoproteins, and the secretion of nascent lipoprotein particles by the liver and small intestine. Further investigation of this problem will lead to additional insights into the modulation by apo E of the metabolism of apo Bcontaining lipoprotein particles. 
Apo E Polymorphism and Atherosclerosis: Direct Evidence
The observed impact of allelic variation at the apo E locus on plasma lipid and lipoprotein levels in normal and dysiipidemic individuals has led to the hypothesis that the apo E polymorphism plays a major role in determining susceptibility to atherosclerosis in man. The e2 allele is associated with lower levels of LDL cholesterol, but predisposes to hypertriglyceridemia; it could, therefore, play a protective role, provided no other condition interacted to raise the plasma levels of atherogenic cholesterol-enriched lipoprotein remnants, and offset its beneficial effect on LDL. On the other hand, the e4 allele, which is associated with higher levels of LDL cholesterol, could favor the development of atherosclerosis. This hypothesis has been tested in survivors of myocardiai infarction (Ml), in patients with angiographically documented coronary heart disease, and in octogenarians. Although the subject is still a matter of controversy, there is more and more evidence that the two less prevalent alleles do, indeed, have separate effects on the development of atherosclerosis.
Studies In Myocardiai Infarction Survivors
Utermann and coworkers 115 estimated the apo E phenotype and allele frequency distributions in 523 survivors of Ml from two centers. In one center, the presence of coronary atherosclerosis was proven by angiography in 168 individuals studied. Two control groups were used for comparison: 1031 blood donors with a younger age distribution and 400 patients of comparable age with neurological dis-ease. Since the two groups had virtually the same apo E frequency distribution, the blood donors were used for statistical comparisons. A lower relative frequency of the e4 allele was found in subjects who had sustained a Ml (0.121 vs. 0.150, all Ml cases vs. blood donors). This is the only study showing a lower prevalence of apo E4 in coronary artery disease. No reference was made to the age or sex distribution, or to the prevalence of major risk factors for CAD, including hyperlipidemia, among the Ml survivors. Upid and lipoprotein levels were not measured, except in five of the seven apo E2 homozygotes in the Ml group. There was no significant difference between Ml patients and controls for e2 and e3 allele frequencies. All five Ml survivors with the E2/2 phenotype were hyperiipidemic with a type III lipoprotein profile, four of them males under 60 years of age. In contrast, none of the 21 e2/e2 homozygotes serving as controls had overt hyperlipidemia. Therefore, type III hyperiipoproteinemia was over-represented in the group of patients with Ml, even though the frequency of the E2/2 phenotype was not different between Ml survivors and controls. This supports the hypothesis that the presence of the e2 allele protects against atherosclerosis as long as hyperiipoproteinemia does not develop.
Kameda and coworkers 116 measured the E3: E2 ratio by densitometry, after isoelectric focusing of VLDL using the method of Weidman and coworkers 117 to identify the apo E-ND phenotype (equivalent to E3/2 and E4/2 combined). They compared 97 survivors of acute Ml with 43 non-agematched controls and found the apo E-ND phenotype to be more frequent in the former (51% vs. 25%, p < 0.02). There was a close association between heterozygosity for e2 and the presence of cholesterol-enriched VLDL. Kameda et al. suggested that a relative deficiency of the e3 allele (rather than an excess of the E2 allele) conferred a risk for atherosclerosis by impairing the clearance of remnant lipoproteins. This higher frequency of the e2 allele (relatively low in normolipidemic individuals in Japan) in Ml is at variance with the findings of Utermann et al. 115 Cumming and Robertson 57 compared a random sample of 239 Ml survivors under the age of 65 with a group of 400 randomly selected controls between 45 and 60 years ( Table 4 ). The mean age was similar in both groups of men and women who were from the same region of northeast Scotland. In the Ml groups, they found a higher relative frequency of E4/3 and a lower relative frequency of E3/2 than expected. Interestingly, the mean age at the time of the first infarction was lower in men of phenotype E4/3 than in those with the other phenotypes. Lipoprotein concentrations and prevalence of associated risk factors for coronary heart disease were not reported. From their data, the allele frequencies in the Ml group for e4, e3, and e2 were 0.207, 0.734, and 0.059, respectively. Only the frequency of 0.233 for the e4 allele in women was significantly different from that of the control group (0.147). These researchers concluded that the presence of the e4 allele might confer an increased risk of Ml at an earlier age, at least in men.
Another study carried out in Germany by Lenzen et al. 118 compared 570 male survivors of Ml who had documented coronary artery lesions at angiography with 624 agematched male factory employees without clinical or ECG evidence of CAD. There was no statistically significant difference in the apo E phenotype or allele frequency distributions between the two groups. However, the alleles e2 and e4 had major effects on total and LDL cholesterol concentrations in both groups. These workers found the same stepwise decreasing gradient in plasma cholesterol concentrations, going from E4/3 to E3/3 to E3/2, in the CAD group as in the control group, even though the plasma cholesterol levels as a whole were much higher in the former than in the latter group ( Figure 6 ). In the Ml survivors, the mean serum cholesterol concentration was 12.6 mg/dl higher in E4/3 subjects and 10.7 mg/dl lower in E3/2 subjects than the levels observed in individuals with the E3/3 phenotype, an overall difference of 23.3 mg/dl between E4/3 and E3/2. In the control group the correspond- ing difference was 17.4 mg/dl (data from Table 2 in reference 118). LDL cholesterol concentrations followed similar trends, but HDL cholesterol and triglycerides did not vary significantly with the apo E phenotype in either group. The apo E polymorphism thus exerts a similar effect on levels of cholesterol In a diseased 118 or hyperlipidemic 56 population as in normolipidemic 54 or randomly selected normal populations. 3 5 3 5 5 5 9 6 0 6 1 Ml occurred an average of 4.6 years earlier in E4/3 than in E3/2 subjects. 118 There were significant differences in the prevalence of apo E isoforms in patients with early (<50 years) and late (s50 years) infarction. Sixty percent of E4/3 phenotypes and 23.7% of E3/2 phenotypes observed were found among subjects with early infarction. Conversely, 40% of E4/3 and 76.3% of E3/2 phenotypes observed were found among the group of subjects who had sustained a late infarction (p < 0.001 in both instances). The discrepancy between this observation and that of Utermann and coworkers 115 is ascribed by the authors to "clinical heterogeneity among Ml survivors." Indeed, not all subjects sustaining an Ml have significant atherosclerotic lesions. For instance, in the study of Lenzen and coworkers 118 60 of 630 Ml patients had little or no coronary atherosclerosis detected by angiography and were excluded, leaving Ml subjects with definite coronary atherosclerosis (>50% stenosis in one or more of the major coronary arteries) for comparison to the control group.
More definitive information regarding the impact of the less frequent apo E alleles on myocardial infarction incidence would, perhaps, be best obtained by examining the allele frequencies in individuals who sustained a myocardial infarction at an early age and in the absence of major CAD risk factors (hypercholesterolemia, hypertension, diabetes, and smoking). The effect of variation at the apo E locus on susceptibility to atherosclerosis may well be masked by stronger risk factors acting independently of the influence of apo E. It is also possible that the effect of an allele at the apo E locus on susceptibility to atherosclerosis may vary among individuals depending on the constellation of other risk factors to which they may be exposed.
Studies In Anglographlcally Documented Coronary Heart Disease
Menzel and coworkers 62 compared the relative frequencies of the apo E alleles and phenotypes in 1000 factory workers in Munster with those estimated for 439 patients with angiographically documented coronary artery disease and 439 patients without coronary artery disease from Munster and Dusseldorf. Patients with CAD were defined as individuals with chest pain and more than 50% reduction in lumen size in one or more coronary vessels (CAD + ); all others were classified as having no CAD (CAD-). The patients were considerably older than the controls. The apo E phenotype distribution was virtually the same in controls and in the CAD+ group. There was, however, a higher frequency of E3/2 in men in the CADgroup as compared with the other two (CAD + and factory workers). Since the lowest cholesterol concentrations were observed in E3/2 patients unaffected by CAD, these researchers considered E3/2 heterozygosity to be a negative risk factor through its "hypocholesterolemic effect." The relative prevalence of major CAD risk factors in the three groups was not reported. Plasma cholesterol and triglycerides were higher in the CAD+ group but HDL cholesterol was significantly lower only in women of the CAD+ group, as compared to the other two groups.
Schmidt and coworkers 119 measured the E2: E3 ratio by densitometry in 83 men and 43 women undergoing coronary angiography for suspected CAD. Those with no lesions or with lesions producing less than 50% luminal narrowing were used as controls (14 men and 13 women). There was no significant difference in the ratio in either sex. Other major risk factors were present; in men cholesterol, triglycerides, LDL cholesterol, and LDL apo B were significantly higher and HDL cholesterol, significantly lower in the CAD+ group than in the controls.
An attempt was made by Reardon and coworkers 120 to associate the apo E phenotypes with variation in severity of coronary atherosclerosis in 65 men and 42 women (mean age 52 ± 8 years) undergoing arteriography for suspected coronary disease. There were no significant differences in scores among men and women with the various apo E phenotypes. There were no E4/4 or E2/2 individuals in this sample of 107 subjects which included smokers, hypertensive individuals, heavy drinkers, diabetics, hyperiipidemics, and subjects treated with thiazides and beta-blockers. The relative allele frequencies were 0.126, 0.799, and 0.074 for e4, e3, and e2, respectively.
In another study, the apo E phenotype distribution was determined in 122 men with angiographically documented CAD (at least one coronary artery with stenosis > 50%). 121 These men were under 65 years of age, free from diabetes and hypertension, and matched for age, relative weight, and smoking habits with 100 male controls who had no signs of vascular disease. No significant difference in apo E phenotype distribution was found between the CAD and control groups. However, hyperlipidemia, as defined in this study, was present in 60% of the CAD subjects and in 30% of the control group. In the CAD group the presence of the e2 allele was associated with hypertriglyceridemia.
The conflicting results obtained in these angiographic studies can be related to differences in sample size and patient selection, to the confounding effect of major CAD risk factors (especially significant hyperlipidemia) which masks the more subtle impact of the apo E alleles, to the use of drugs altering the lipoprotein profile, and to differences in the definition of coronary artery disease. The definition of "significant CAD" which uses a cut-off point of 50% stenosis on angiography is essentially a measure of disease severity. Patients with less than 50% stenosis do not necessarily constitute an adequate control group (a 30% to 40% luminal narrowing in three arteries still reflects the presence of atherosclerosis). The sensitivity of angiographic techniques currently in use for assessment and scoring of severity of coronary lesions is still low, with a large degree of technical and subjective variability, making severity scoring a relatively gross assessment. Furthermore, severe atherosclerosis may occur in the periphery in the absence of significant lesions in the coronary bed. Finally, differences in age and sex distribution may account for some of the discrepancies observed. Future studies of the relationship between atherosclerosis and apo E genotypes should be designed to exclude or control for these confounding factors and be carried out in "normclipidemic" individuals with CAD.
Studies In Populations at Various Levels of Risk
The Finnish population has the highest incidence of myocardial infarction in the world and ranks among those with the highest cholesterol levels. 122 A high frequency of the 64 allele (0.227) and a low frequency of the e2 allele (0.041) was found in 615 unrelated Finns in Helsinki studied by Ehnholm and coworkers 59 (Table 1 ). The apo E phenotype distribution and allele frequencies are given for a subgroup from this sample (see Table 4 ). The highest concentrations of plasma cholesterol, LDL cholesterol, and apo B measured in this subset of 207 individuals were seen in the E4/4 and the E4/3 phenotypes and the lowest, in the E3/2, E4/2, and E2/2 phenotypes. In a smaller subset of E4/4, E4/3, and E3/2 subjects contrasted with age-, sex-, and weight-matched apo E3/3 subjects used as controls, cholesterol and LDL cholesterol were significantly higher in individuals with the E4/4 and E4/3 phenotypes.
In contrast, Asian populations with a low incidence of CAD have lower frequencies of both E2 and e4 alleles (Tables 1 and 4 ). 50 -53123 Indeed, the Japanese rank among the populations of the world with the lowest incidence of CAD and the lowest levels of plasma cholesterol 122 and have the lowest reported relative frequencies for both e2 (except for one Amerindian sample, Table 1 ) and e4, 0.035 and 0.112, respectively (weighted average of data from three studies, Table 1 ). For the Chinese, the frequencies are 0.084 and 0.064 for e2 and e4, respectively (weighted average of data from two studies, Table 1 ). However, there are large differences in cholesterol levels and other CAD risk factors among individuals bearing the same apo E phenotypes who come from high-or low-risk populations. In view of the marked contrast in apo E allele frequencies between populations at the extremes of risk, we may tentatively propose a role for e4 in predisposition to CAD.
One indirect way to assess the impact of the apo E alleles on coronary artery disease is to study individuals who have survived to old age and have therefore avoided earlier death from CAD. If the e4 allele constitutes a risk factor for CAD, its frequency should be reduced in this older age group. Conversely, if the e2 allele has a protective effect and if no intervening factor has promoted a secondary increase in atherogenic remnant particles, a greater frequency of this allele would be expected in the elderly. These possibilities have been investigated in one study. 124 -125i12fi In 236 autonomous ambulatory octogenarians who were mentally fit to submit to a health questionnaire and free of chronic debilitating disease, a lower overall frequency of the e4 allele was found (0.087 vs. 0.152 in a control sample of 102 normolipidemic volunteers from the city of Ottawa; p < 0.025; Table 4 ). Unexpectedly, there was a marked sex difference; although there was a lower frequency of e4 in both women and men, the relative frequency of the e2 allele tended to be higher in men only (p < 0.075, men vs. women). Examination of the lipoprotein profiles in these subgroups demonstrated that there were more hyperlipidemic individuals among women than among men and that most men with an e2 allele were normotriglyceridemic, except for the only subject with an E2/2 phenotype who was mildly hyperlipidemic. Octoge-narians with an e4 allele had the same mean LDL cholesterol concentrations as those wtth the E3/3 phenotype, in contrast to findings in the younger normal population 54 ' 118 or in younger CAD patients. 118 The evidence for a role of the apo E polymorphism in modulating the susceptibility of an individual to atherosclerosis is still fragmentary and controversial. A number of points emerge. Individuals who have the e4 allele have higher plasma cholesterol and LDL cholesterol levels and develop coronary heart disease at an earlier age than those with the other alleles. The frequency of the e4 allele is high in the Finns in whom the frequency of CAD is high, and low in the Japanese and the Chinese in whom CAD mortality is low. The lower frequency of e4 in octogenarians suggests that relatively fewer bearers of the e4 allele may survive to this age. A higher frequency of the e4 allele in coronary artery disease subjects was found in only one of several studies; this discordant fact has yet to be explained. Age appears to have a major influence on the impact of the apo E aJleles on CAD; in the younger age group wtth CAD there is a higher proportion of E4/3 than in the older one, whereas the opposite applies for E3/2. This is consistent with the concept that among atherogenic particles, LDL is more deleterious than 6-VLDL. Plasma concentrations of the former (LDL) are higher in the presence of the e4 allele and take their toll earlier, whereas the levels of the latter (cholesterol-and triglyceride-rich I3-VLDL), which may be raised in the carriers of the e2 allele, take more time to exert their atherogenic potential. One could also argue that the deleterious effect of the remnant particles present in subjects heterozygous for the e2 allele is offset by the beneficial effect of having low LDL cholesterol levels. Another source of discrepancy may be the relative proportion of hypercholesterolemics (more of whom have the e4 allele) and hypertriglyceridemics (more of whom have the e2 allele) recruited in the CAD sample. Finally, a bias could be introduced by the selective influence of major risk factors that are stronger than, and act independently of, the impact of apo E alleles. The effects of the apo E alleles on lipid levels in normal and diseased populations are very similar, so that the impact of the alleles in a diseased population is a function of the shift in their relative frequency. The findings so far point to the e4 allele as a potential factor conferring a genetic predisposition to CAD in some individuals exposed to an unfavorable environment. Studies in normolipidemic individuals who have developed CAD in the absence of other major risk factors and prospective studies should settle this question.
A protective role for the e2 allele against atherosclerosis in normolipidemic individuals is suggested by the observations: 1) that this allele is associated with lower LDL cholesterol levels, 2) that its relative frequency is lower in the Finns with high CAD mortality and in subjects with coronary heart disease, and 3) that the frequency is higher in male octogenarians who have, by definition, avoided CAD death. On the other hand, this effect may be partially offset by the propensity of individuals with the e2 allele to develop hypertriglyceridemia and cholesterol-enriched atherogenic lipoproteins in response to additional genetic or environmental challenges. The equilibrium between these opposing effects might be altered by hormonal influences, which would account for the sex difference observed in the octogenarians and for the effect of estrogen withdrawal on the expression of type III hyperlipidemia. 12S ' 127 Complex gene-gene and gene-environment interactions determine the final impact of the e2 allele on CAD risk, as exemplified by the fact that most E2/2 subjects detected among the CAD patients were hyperlipidemic. 115
Impact of Apo E on Risk
The apo E locus has a major influence on plasma LDL concentration which can be explained by differences in the metabolic behavior of the three major apo E isoforms. This raises questions as to the quantitative importance of this effect relative to other risk factors for CAD and as to its epidemiologic implications. By definition, the relative Impact" of an allele on levels of a variable in the population at large is the product of the "average effect" and the frequency of the allele. The average effect, as estimated by Sing and Davignon, 54 of the e2 allele on plasma cholesterol is in the opposite direction to, and twice as large as, that of the e4 allele (Figure 2 ), whereas the relative frequency of e2 in a Caucasian population is only half of that of e4. Therefore, although the effects of these alleles differ in determining the cholesterol concentration of an individual, their impact on the variability of plasma cholesterol in the population is similar in magnitude. What are the implications of these differences in effect and in impact? Figure 7 gives the expected frequency distribution of plasma cholesterol levels for each of the six apo E phenotypes estimated from the Ottawa study 54 and the risk curve for CAD associated with cholesterol estimated from the Framingham experience. 128 The area under each curve gives the estimated proportion of individuals in the Ottawa population with the corresponding phenotype. The expected risk associated with the average cholesterol level of each phenotype is denoted on the risk curve. The average changes in individual cholesterol levels attributable to the various apo E phenotypes and the corresponding changes in risk are smaller than those caused by, for example, familial hypercholesterolemia; however, the relative frequencies of the e2 and e4 alleles in the general population are far greater than the relative frequency of the LDL receptor gene defects that cause familial hypercholesterolemia, so their effects are exerted on a much larger segment of the population, and they thus have a greater impact on the epidemiology of CAD risk.
There is a growing body of evidence for a protective, anti-atherogenic role for the e2 allele in the absence of any environmental or genetic challenge which promotes the accumulation of triglyceride-and cholesterol-rich remnant particles. Similarly, there are indications that the e4 allele may be atherogenic in an unfavorable environment. Sing et al. 14 used the logistic risk equation from the Framingham study 128 and the Ottawa data 54 presented in Figure 7 to estimate the average risk of CAD associated wtth the e2, e3, and e4 alleles. Their calculations suggest that the subpopulation carrying the e4 allele has an average risk 1.43 times as great as that for the group carrying the e2 allele. In terms of interindividual variation, although 7% of the variance in cholesterol concentration is associated with allelic variation in the apo E gene locus, only 2.8% of the variation in risk may be ascribed to this single gene locus. Although this is a small fraction of total variability in CAD risk, it constitutes a large contribution by a single genetic factor. It should be emphasized that the simultaneous estimation of the impact of the apo E polymorphism on cholesterol levels and risk of CAD has not been carried out for any population. Prospective studies in which apo E phenotypes, cholesterol, other risk factors, and CAD endpoints are measured will provide more exact estimates of the relative impact of the apo E polymorphism on CAD incidence in the population at large.
New Perspectives and Future Avenues of Research
Major advances have been made in the understanding of the structure, function, and genetics of apo E, but many unanswered questions remain as to the role of the apo E polymorphism in atherogenesis. Recent reports have opened new avenues of research into apo E and its interactions and associations which may bear on the atherogenic potential of this functionally polyvalent molecule. Of interest are current studies of the molecular biology of the gene, the exploration of its evolutionary aspects, recent data on drug response modulation and a putative role for apo E in nerve regeneration and immunoregulation.
Since the cloning and sequencing of apo E cDNA and genomic DNA, the molecular biology of apo E has been investigated extensively. 20 " 27 As mentioned earlier, the apo E gene is on chromosome 19 tightly linked to the genes for apo C-l and apo C-ll and more distantly linked to the genes for the C3 component of complement and the gene locus associated with myotonic dystrophy. It is also distantly linked to the gene for the LDL receptor. 19 " 22129 Because of the close association of the apo E gene to these other genes on chromosome 19, it may be possible to use polymorphisms in the apo E protein or gene 130 as markers for mutations in these closely linked genes when performing genetic studies in families. The three apolipoprotein genes are closely linked and there is thus potential for their coordinate regulation. The regulatory elements for the transcription of the apo E gene are currently being investigated to clarify the factors that regulate apo E synthesis. 131 The study of evolutionary aspects of apo E may add to our understanding of its role in humans. Many avian species do not have any apo E in plasma 132 ' 133 and may utilize apo A-l in place of apo E in lipid and lipoprotein metabolism. 134 In nonhuman primate populations, only one major apo E isoform is found which, depending on the species, is predominantly associated with LDL and HDL fractions. 135 Species susceptibility to atherosclerosis has been associated with differences in lipoprotein profiles, especially in terms of the proportion of cholesterol transported by LDL and HDL. Further studies should be carried out, taking into consideration variability in plasma apolipoproteins among species with differing degrees of susceptibility to atherosclerosis. In humans, the frequencies of the apo E alleles are quite stable among many distinct populations and it will be important to determine the factors responsible for this stability. It is possible that a selective disadvantage of an allele in one given ecological context might become an advantage in another, and it may be useful to consider the impact of the apo E polymorphism on major clinical endpoints other than atherosclerosis, such as malignancies. 138 The modulation of lipoprotein metabolism by apo E has been reviewed above, but there are undoubtedly other processes regulated by apo E. Apo E is necessary for the efficient conversion of VLDL remnants to LDL, but the mechanism is poorly understood at present. In addition, apo E may have an important function in reverse cholesterol transport. 32 Little is known about the regulation of the synthesis and secretion of apo E, apo B, and apo B-containing lipoproteins, but the modulation of plasma lipoprotein metabolism by apo E probably plays a role in regulating these processes. Recent evidence of great interest suggests that the polymorphic forms of apo E may play a role in modulation of the lipoprotein response to drug therapy. 137 It was found that among patients with LDL receptor defects, individuals with the e4 allele responded better to the cholesterol-lowering effect of probucol than subjects with no E4 in their apo E phenotype.
Atherosclerosis is a multifaceted disorder, and lipoproteins form only one of the many links intervening between inception of the lesion and development of the complicated plaque or between the gene and the CAD endpoint. Recent reports point to other roles of apo E involving the immune system and tissue regeneration which might provide clues for a more direct action on the atherogenic process at the arterial wall. Apo E is present in the cerebrospinal fluid, 138 and recent evidence suggests a role for apo E in the central nervous system as well as in peripheral nerve regeneration, a process which involves macrophages. 30 ' 31 > ^1 3 S i 139 There is also evidence suggesting a role for apo E in the regulation of the immune system. 140 " 143 Binding of apolipoprotein E or B to specific cell surface receptors suppresses the proliferation of lymphocytes, 140 ' 142 and apo E has the ability to suppress phytohemaglutinin-activated phospholipid turnover. 141 In addition, apo E is synthesized and secreted by macrophages 32 which are involved in foam cell formation. It is known that chemotactic factors, growth promoters and inhibitors, and oxidative processes affect macrophage behavior and foam cell formation. 144145 It would be important to determine whether, in the arterial wall, apo E is involved in any of these processes, especially the mobilization and differentiation of monocyte-derived macrophages and smooth muscle cells destined to become foam cells.
Summary
The apo E locus contributes to determining the variation in plasma cholesterol levels of healthy and diseased populations. It also influences the expression of hyperiipidemia and appears to modulate the susceptibility to atherosclerosis in a complex multifactorial interaction. There is evidence that the presence of apo E2 is protective, whereas that of apo E4 predisposes to coronary artery disease. The burden of proof, however, lies on future, well-designed clinical trials and prospective studies.
The study of the biological significance of the apo E polymorphism in humans has emphasized the importance of gene-gene and gene-environment interactions in the pathogenesis of hyperiipidemia and atherosclerosis. The apo E polymorphism involves the coding region of the apo E gene and results in alterations of the gene product which, in turn, either directly or secondarily affect the metabolic fate of the lipoprotein particles. Rapid advances in knowledge over the last decade have provided a metabolic explanation for the observation of the opposite effects of the e4 and the e2 alleles on lipoprotein levels. Apo E2 has lower receptor binding affinity which results in delayed clearance of apo E2-bearing lipoprotein particles from plasma. Apo E4 is distributed differently from apo E3 between VLDL and HDL, is degraded more rapidly than apo E3, and may enhance the catabolism of E4-bearing particles, leading to other alterations in lipoprotein metabolism which result in elevated levels of LDL. In view of the significant opposite impacts of the E4 and the e2 alleles on plasma LDL cholesterol concentrations, it is evident that determination of the apo E phenotype will become a useful adjunct to the assessment of the cardiovascular risk profile of an individual. In addition, the relationship between the e2 allele and type III hyperiipoproteinemia provides a valuable model for the study of complex genetic interactions in the pathogenesis of hyperiipidemia. The further study of apo E and its interactions shows great promise for a deeper comprehension of the pathogenesis of atherosclerosis.
